5 Einträge |
Seite 1 / 1
![]() |
Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. |
Chan A, Delaloge S, Holmes FA, Moy B, Iwata H, Harvey VJ, Robert NJ, Silovski T, Gokmen E, von Minckwitz G, Ejlertsen B, Chia SK, Mansi J, Barrios CH, Gnant M, Buyse M, Gore I, Smith J, Harker G, Masuda N, Petrakova K, Zotano AG, Iannotti N, Rodriguez G, Tassone P, Wong A, Bryce R, Ye Y, Yao B, Martin M |
The Lancet. Oncology. 2016 Feb 10. pii: S1470-2045(15)00551-3. doi: 10.1016/S1470-2045(15)00551-3 |
PMID: 26874901 |
Characterization of patients who received prior chemotherapy for advanced breast cancer (ABC) in BOLERO-2. |
Campone M, Lebrun F, Noguchi S, Pritchard KI, Burris HA, Beck JT, Ito Y, Bachelot T, Pistilli B, Melichar B, Petrakova K, Arena FP, Erdkamp F, Harb WA, Litton JK, Brechenmacher T, El-Hashimy M, Taran T, Gnant M |
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017 Jan 31. doi: 10.1200/jco.2013.31.26_suppl.151 |
PMID: 28136563 |
Patient-reported physical, emotional, and social functioning in advanced breast cancer: Insights from BOLERO-2. |
Hortobagyi GN, Lebrun F, Beck JT, Neven P, Baselga J, Petrakova K, Dakhil SR, Sabatini S, Komorowski A, Chouinard EE, Young RR, Gnant M, Pritchard KI, Zhang J, Ziemiecki R, Brechenmacher T, Taran T, Sahmoud T, Noguchi S |
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017 Jan 31. doi: 10.1200/jco.2013.31.26_suppl.155 |
PMID: 28136549 |
Everolimus for postmenopausal women with advanced breast cancer: Updated results of the BOLERO-2 phase III trial. |
Noguchi S, Pritchard KI, Burris HA, Rugo HS, Gnant M, Hortobagyi GN, Latini L, Yardley DA, Melichar B, Petrakova K, Harb W, Feng W, Cahana A, Taran T, Campone M, Baselga J, Sahmoud T, Lebwohl DE, Piccart-Gebhart MJ |
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017 Feb 1. doi: 10.1200/jco.2012.30.27_suppl.99 |
PMID: 28146687 |
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. |
Martin M, Holmes FA, Ejlertsen B, Delaloge S, Moy B, Iwata H, von Minckwitz G, Chia SKL, Mansi J, Barrios CH, Gnant M, Tomašević Z, Denduluri N, Šeparović R, Gokmen E, Bashford A, Ruiz Borrego M, Kim SB, Jakobsen EH, Ciceniene A, Inoue K, Overkamp F, Heijns JB, Armstrong AC, Link JS, Joy AA, Bryce R, Wong A, Moran S, Yao B, Xu F, Auerbach A, Buyse M, Chan A |
The Lancet. Oncology. 2017 Nov 13. pii: S1470-2045(17)30717-9. doi: 10.1016/S1470-2045(17)30717-9 |
PMID: 29146401 |
5 Einträge |
Seite 1 / 1
![]() |